PharmaShots | Incisive News in 3 Shots

Subscribe Now

recurrent ovarian cancer

Zai Lab's Zejula (niraparib) Receives NMPA's Approval as Maintenance Therapy for Patients with Recurrent Ovarian Cancer in China

Zai Lab's Zejula (niraparib) Receives NMPA's Approval as Maintenance Therapy for Patients with Recurrent Ovarian Cancer in China

December 30, 2019

GSK's Zejula (niraparib) Receives FDA's Approval for Late-line Treatment in Women with Recurrent Ovarian Cancer

GSK's Zejula (niraparib) Receives FDA's Approval for Late-line Treatment in Women with Recurrent Ovarian Cancer

October 24, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us